134 related articles for article (PubMed ID: 20511165)
1. Comparison among immunologically different subtypes of 595 untreated multiple myeloma patients in northern China.
Zhang L; Qi JY; Qi PJ; Wang YF; Zou DH; Yao HJ; An G; Yi SH; Li Q; Qiu LG
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):197-204. PubMed ID: 20511165
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
4. [Clinical features and survival of Chilean patients with multiple myeloma].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2007 Sep; 135(9):1111-7. PubMed ID: 18064364
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
6. [The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma].
Li J; Zhao Y; Luo SK; Huang BH; Zhang GC; Peng AH; Zheng D; Su C; Xu DR; Tong XZ; Gu JL; Ding Y
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2140-3. PubMed ID: 19080477
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
8. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting outcome of patients with multiple myeloma.
Basit A; Siddiqui N; Hameed A; Muzaffar N; Athar S
J Ayub Med Coll Abbottabad; 2014; 26(3):376-9. PubMed ID: 25671952
[TBL] [Abstract][Full Text] [Related]
11. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.
Chong YP; Kim S; Ko OB; Koo JE; Lee D; Park SH; Park SJ; Lee D; Kim SW; Suh C
J Korean Med Sci; 2008 Oct; 23(5):819-24. PubMed ID: 18955788
[TBL] [Abstract][Full Text] [Related]
12. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.
Hsiao LT; Yang CF; Yang SH; Gau JP; Yu YB; Hong YC; Liu CY; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Eur J Haematol; 2012 Feb; 88(2):159-66. PubMed ID: 21973045
[TBL] [Abstract][Full Text] [Related]
13. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients.
Shimamoto Y
Cancer Detect Prev; 1995; 19(5):426-35. PubMed ID: 7585729
[TBL] [Abstract][Full Text] [Related]
14. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
15. [Survival prognosis factors in multiple myeloma].
Younes M; Hachfi H; Hammouda F; Younes K; Ben Hammouda S; Jguirim M; Zrour S; Béjia I; Touzi M; Bergaoui N
Tunis Med; 2014 Jun; 92(6):399-405. PubMed ID: 25741841
[TBL] [Abstract][Full Text] [Related]
16. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
17. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors affecting survival in multiple myeloma].
Tornóczky J; Tóth A; Sziládi E; Hoffmann E; Liszátz M
Orv Hetil; 1990 Aug; 131(31):1679-84. PubMed ID: 2205822
[TBL] [Abstract][Full Text] [Related]
19. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria.
Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Lal R; Singhal S; Mehta J; Horton C; Treleaven J
Bone Marrow Transplant; 2001 Jul; 28(1):29-37. PubMed ID: 11498741
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma in the region of Bursa, Turkey: a retrospective analysis.
Ozkalemkaş F; Ali R; Tunali A; Ozkocaman V; Ozyardimci C; Ozçelik T
J Environ Pathol Toxicol Oncol; 1996; 15(2-4):267-70. PubMed ID: 9216819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]